The efficiency of stem cell transplantation is limited by low cell retention. Intracoronary (IC) delivery is convenient and widely used but exhibits particularly low cell retention rates. We sought to improve IC cell retention by magnetic targeting. Rat cardiosphere-derived cells labeled with iron microspheres were injected into the left ventricular cavity of syngeneic rats during brief aortic clamping. Placement of a 1.3 Tesla magnet ϳ1 cm above the heart during and after cell injection enhanced cell retention at 24 h by 5.2-6.4fold when 1, 3, or 5 × 10 5 cells were infused, without elevation of serum troponin I (sTnI) levels. Higher cell doses (1 or 2 × 10 6 cells) did raise sTnI levels, due to microvascular obstruction; in this range, magnetic enhancement did not improve cell retention. To assess efficacy, 5 × 10 5 iron-labeled, GFP-expressing cells were infused into rat hearts after 45 min ischemia/20 min reperfusion of the left anterior coronary artery, with and without a superimposed magnet. By quantitative PCR and optical imaging, magnetic targeting increased cardiac retention of transplanted cells at 24 h, and decreased migration into the lungs. The enhanced cell engraftment persisted for at least 3 weeks, at which time left ventricular remodeling was attenuated, and therapeutic benefit (ejection fraction) was higher, in the magnetic targeting group. Histology revealed more GFP + cardiomyocytes, Ki67 + cardiomyocytes and GFP − /ckit + cells, and fewer TUNEL + cells, in hearts from the magnetic targeting group. In a rat model of ischemia/reperfusion injury, magnetically enhanced intracoronary cell delivery is safe and improves cell therapy outcomes.
INTRODUCTION
stem cells in biomaterials (23), by novel delivery methods (26) , or as 3D aggregates (19) produced better retention and engraftment. Magnetic attraction can focus The success of cell therapy relies on effective delivery into the desired region. In the heart, retention of iron-tagged therapeutic agents (drugs, genes, cells, etc.) within a target region (29) . We have successfully used transplanted cells remains a major challenge: venous washout potentiated by cardiac contraction results in magnetism to counteract venous washout and improve cell retention in the contracting heart, with cells deliv-substantial cell loss during and immediately after delivery (1, 34) . The challenges are particularly acute for cells ered by intramyocardial (IM) injection (9) . Short-term retention and long-term engraftment were dramatically delivered via the intracoronary (IC) route, where cell retention is quite low (1, 4, 5) . Nevertheless, IC delivery improved, with enhanced functional and structural benefits. Although promising in concept, the clinical utility has proven to be safe, feasible, and reproducible (21), and the ease of clinical application is a big plus. For of that model was limited, because we used permanent coronary artery ligation to create the injury and open-these reasons, we sought to improve the efficacy of IC cell delivery using readily translatable methods.
chest direct injection to deliver the cells. In real clinical scenarios, acute myocardial infarction (AMI) patients Physical approaches may help in retaining cells within targeted regions long enough to enable biological usually first undergo reperfusion; if cell therapy is used, the IC route is favored for its established safety and integration. It has been reported that transplantation of feasibility. It is unknown whether IC cell delivery also representative wells and the plate was incubated at 37°C for 1 h. Then, absorbance was measured by a Spectra stands to benefit from magnetic targeting. Here, we investigated the safety and efficacy of magnetic enhance-Max TM M5 plate reader (Molecular Devices, Sunnyvale, CA). For Western blot analysis of apoptosis marker cas-ment for IC delivery of cardiosphere-derived cells (CDCs) in a rat model of acute ischemia/reperfusion. pase-3, the equivalent total protein from control and SPM-labeled CDCs was loaded onto sodium dodecyl MATERIALS AND METHODS sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) General Study Design gels, and then transferred to polyvinylidene fluoride (PVDF) membranes. After overnight blocking in 3% We first conducted a dose-ranging study in a group milk Tris-buffered saline Tween-20 (TBS-T), memof noninfarcted animals to determine the optimal cell branes were incubated with 1:1000 mouse anti-caspasedose for IC delivery of CDCs. The goal was to maxi-3 antibody and 1:3,000 rabbit anti-β-actin monoclonal mize cell retention without causing microembolic injury antibody (Lifespan Bioscience, Seattle, WA). The (17) . After establishing a maximal safe IC dose, we used appropriate horseradish peroxidase-conjugated secondthat dose in a pivotal study to evaluate the efficacy of ary antibodies were used, and then the blots were visualmagnetic enhancement. Three treatment groups were ized by using SuperSignal West Femto maximum included: 1) Control group: IC infusion of vehicle (PBS) sensitivity substrate (Thermo Scientific, Rockford, IL) only; 2) Fe-CDC group: IC infusion of iron-labeled and exposed to Gel DocTM XR System (Bio-Rad Lab CDCs without a magnet; 3) Fe-CDC + magnet group;
INC, Hercules, CA). Cell apoptosis was also assessed IC infusion of iron-labeled CDCs with a magnet placed by terminal deoxynucleotidyl transferase dUTP nick end above the left ventricle (LV) during and after infusion. labeling (TUNEL) staining (In Situ Cell Death Detection We did not include a nonlabeled CDC group here Kit, TMR red, Roche, Germany). Cell nuclei were counbecause we have found no effects of iron loading per se terstained with 4′,6-diamidino-2-phenylindole (DAPI). (9) . To increase relevance to reperfused AMI, we used a coronary occlusion/reperfusion model.
Animal Model Rat CDC Culture and SPM Labeling
Animal care was in accordance to the Institutional Animal Care and Use Committee (IACUC) guidelines at Rat CDCs were generated and maintained as pre-Cedars-Sinai Medical Center. A rat ischemia/reperfusion viously described (9, 11, 12) . After 2 passages, rat CDCs model was used. Female WKY rats (Charles River Labwere labeled with flash red fluorescence-conjugated oratories, Wilmington, MA) (n = 82 total) underwent superparamagnetic microsphere (SPM) particles by left thoracotomy in the 4th intercostal space under gencoincubation of the cells with SPMs (at a 500:1 SPM/ eral anesthesia. The heart was exposed and myocardial cell ratio) for 24 h. SPM labeling was confirmed by infarction was produced by 45-min ligation of the left microscopic detection of flash red fluorescence (Ex: 660 anterior descending coronary artery, using a 7-0 silk nm; Em 690 nm) and Prussian blue staining. For Prussuture. After that, the suture was released to allow corosian blue staining, SPM-labeled and unlabeled cells nary reperfusion. Twenty minutes later, cells were were fixed in 2% glutaraldehyde for 10 min at 4°C, and injected into the left ventricle cavity during a 25-s temthen immersed in 1% potassium ferrocyanide and 3% porary aorta occlusion with a looped suture. For mag-HCl solution (Sigma, St. Louis, MO) for 30 min. After netic targeting, a 1.3 Tesla circular NdFeB magnet several washes with D.I. water, cell nuclei were counter (Edmund Scientifics, Tonawanda, NY) was placed stained with nuclear fast red (Sigma) for 5 min. Then above the heart during and after the cell injection for a the cells were washed again with D.I. water two times. certain period of time. The chest was closed and the After dehydration with methanol (three washes, 70%
animal was allowed to recover after all procedures. The once and 100% twice) and xylene, the slides were dose ranging study was conducted in rat hearts without finally mounted in DPX mounting media (Sigma) ischemia/reperfusion injury. before observation.
Fluorescence Imaging In Vitro Toxicity Experiment
The proliferation rates of SPM-labeled and control Representative animals from each treatment group were euthanized at different time points after cell injec-CDCs were assessed with cell counting kit-8 (CCK-8; Dojindo Molecular Technologies Inc., Rockville, tion for fluorescence imaging. The hearts were placed in an IVIS 200 imaging system (Caliper Life Sciences, MD). The manufacturer's instructions were followed. Briefly, cells were seeded at an initial seeding density Mountain View, CA) to detect flash red fluorescence. Extensive PBS washing was performed to remove any of 2,000 cells per well of a 96-well plate. At predetermined time points, the CCK-8 reagent was added into cells adherent to the epicardium. Excitation was set at 640 nm and emission was set at 680 nm. Exposure time The percentage of viable myocardium as a fraction of the scar area (risk region) was quantified as described (32) . was set at 5 s and kept the same during the entire imaging session. Hearts from the control group (animals Histology receiving normal saline) were also imaged as controls For histology analysis, a subpopulation of animals in for background noise. each group received Fe-CDCs or CDCs overexpressing green fluorescent protein (GFP). The animals were Quantification of Engraftment by Real-Time PCR euthanized and the hearts were harvested and frozen in Quantitative PCR was performed 24 h and 3 weeks OCT compound. Sections every 100 µm of the infarct after cell injection in five animals from each celland infarct border zone area (8 µm thickness) were preinjected group to quantify cell retention/engraftment. pared and immunocytochemistry was performed using We injected CDCs from male donor WK rats into the the following primary antibodies: rabbit anti-GFP myocardium of female recipients to utilize the detection (Abcam, Cambridge, MA, USA), mouse anti-CD68 of sex-determining region Y (SRY) gene located on the (Abcam), mouse anti-α sarcomeric actin (α-SA; Sigma), Y chromosome as a target. The whole heart was harmouse anti-α-smooth muscle actin (α-SMA; Sigma), vested, weighed, and homogenized. Genomic DNA was rabbit anti-von Willebrand factor (vWF; Abcam), rabbit isolated from aliquots of the homogenate corresponding anti-Ki67 (Abcam), and rabbit anti-ckit (Abcam). Secto 12.5 mg of myocardial tissue, using commercial kits ondary antibodies were also purchased from Abcam. (DNA Easy minikit, Qiagen). The TaqMan assay Images were taken by a Leica TCS SP5 X confocal (Applied Biosystems, Carlsbad, CA) was used to quanmicroscopy system. tify the number of transplanted cells with the rat SRY gene as template (forward primer: 5′-GGA GAG AGG ELISA for Cardiac Troponin I, Transferrin, CAC AAG TTG GC-3′, reverse primer: 5′-TCC CAG and Ferritin CTG CTT GCT GAT C-3′, TaqMan probe: 6FAM
All assays were run according to manufacturer's pro-CAA CAG AAT CCC AGC ATG CAG AAT TCA G tocol [Rat Cardiac Troponin-I (cTnI) ELISA, Life Diag-TAMRA; Applied Biosystems). A standard curve was nostics, cat. # 2010-2-HS; Rat Transferrin and Rat generated with multiple dilutions of genomic DNA iso-Ferritin, Immunology Consultants Laboratory Inc, cat.# lated from male hearts to quantify the absolute gene E-25TX and E-25F]. Serum samples were assayed undicopy numbers. All samples were spiked with equal luted for the cTnI ELISA. Serum was diluted 1:40,000 amounts of female genomic DNA as control. The copy for transferrin and 1:40 for ferritin analysis using the number of the SRY gene at each point of the standard provided sample buffer. The absorbance was measured curve was calculated with the amount of DNA in each at 450 nm at the assay endpoint and the values of all sample and the mass of the rat genome per cell. For each analytes were expressed in nanograms per milliliter. reaction, 50 ng of template DNA was used. Real-time PCR was performed with an Applied Biosystems 7900
Statistical Analysis HT Fast real-time PCR system. All experiments were Results are presented as mean ± SD unless specified performed in triplicate. Cell numbers per milligram of otherwise. Statistical significance between baseline and heart tissue and percentages of retained cells of the total 3-week left ventricle ejection fractions (LVEFs) was injected cells were calculated. determined using two-tailed paired Student's t-test. All the other comparisons between any two groups were Morphometric Heart Analysis performed using two-tailed unpaired Student's t-test. Comparison among more than two groups was analyzed For morphometric analysis, seven animals in each by one-way ANOVA followed by Bonferroni post hoc group were euthanized at 3 weeks (after cardiac function test. Differences were considered statistically significant assessment) and the hearts were harvested and frozen in when p < 0.05. OCT compound. Sections every 100 µm (8 µm thickness) were prepared. Masson's trichrome staining was RESULTS performed as described by the manufacturer's instruc-
Labeling of Rat CDCs With Superparamagnetic tions [HT15 Trichrome Staining (Masson) Kit; Sigma].
Microspheres (SPMs) Images were acquired with a PathScan Enabler IV slide scanner (Advanced Imaging Concepts, Princeton, NJ).
Rat CDCs were labeled with flash red fluorescenceconjugated SPM particles at a ratio of 500:1 (SPMs/ From the Masson's trichrome-stained images, morphometric parameters including viable myocardium, scar cells) by spontaneous endocytosis. Fluorescent microscopy and Prussian blue staining confirmed particle size, infarcted wall thickness, and LV cavity area were measured in each section with NIH ImageJ software. uptake ( Fig. 1A, B ). Nonlabeled cells did not exhibit flash red fluorescence or Prussian blue staining ( Fig. 1A , Fe-CDC retention. As a complementary means of measuring retention, we transplanted male Fe-CDCs into B, insets). Labeled cells are hereafter called Fe-CDCs for brevity. The proliferation rates of Fe-CDCs and female recipient hearts to enable the use of Y chromosome-specific PCR to quantify the exact numbers of CDCs were indistinguishable (Fig. 1C ). TUNEL staining and Western blot analysis of caspase-3 confirmed cells per milligram of heart tissue (36) . In the dose ranging study, animals that received magnetically targeted that iron labeling did not induce apoptosis in Fe-CDCs ( Fig. 1D ). These findings confirm that this particular and nontargeted IC Fe-CDCs were sacrificed at 24 h for assessment of cell retention and myocardial injury. In SPM particle, loaded as described, has minimal toxicity on cells (9, 27, 28) .
excised hearts, FLI revealed that flash red intensity increased with escalating cell doses ( Fig. 2A) 3, 5 × 10 5 cells). At higher doses (1 and 2 × 10 6 cells), respectively). Consistent with the FLI results, the numbers of cells retained increased with escalating infused however, epifluorescence was comparable in the Fe-CDC and Fe-CDC + magnet groups. High-intensity cell doses ( Fig. 2B ). At the three lowest doses, magnetic targeting enhanced cell retention by 5.2-6.4-fold (p < regions were detected in both groups (circled with pink), indicating robust cell retention in those zones. 0.05). At the two highest doses, cell retention was comparable in the Fe-CDC and Fe-CDC + magnet groups It is possible to overdose IC CDCs due to the potential for microvascular plugging (17) . To maximize cell (p = 0.14 and p = 0.15, respectively). sTnI levels from both cell treatment groups at the three low doses were retention without inducing myocardial damage, we correlated cell retention (by real-time PCR) with serum tro-comparable to those from control infusions, but sTnI was bumped up in both groups when 1 or 2 × 10 6 cells ponin-I (sTnI, measured by ELISA) to yield dose/ retention and dose/injury relationships ( Fig. 2B , C, were infused (p < 0.001 vs. control). To verify that the elevation of sTnI is due to microembolization (17), rep-percentage of blocked vessels (Fig. 3B ) increased dramatically when the dose was escalated from 5 × 10 5 to resentative hearts were cryosectioned and analyzed for covisualization of alpha smooth muscle actin (αSMA)-1 × 10 6 , rationalizing the increment in sTnI between those two doses. Again, there was no difference between positive blood vessels and Fe-CDCs (flash red fluorescence). No microemboli were detected at the dose of the Fe-CDC and Fe-CDC + magnet groups, indicating that magnetic targeting itself does not induce or worsen 5 × 10 5 cells in either group (Fig. 3A, left two panels) . Fe-CDCs (magenta) were readily detected within the embolic injury. Interestingly, the Fe-CDC + magnet group had more unblocked cell-containing blood vessels blood vessels (green), but the vessels were still patent. At the dose of 1 × 10 6 cells, clear evidence of embolism ( Fig. 3C ; p < 0.005), consistent with the observed increase in cell retention without sTnI elevation. Based was seen as many blood vessels were completely occluded by cell clumps (Fig. 3A, right two panels) . The on these results, we chose the largest cell infusion dose without microembolic injury (5 × 10 5 cells) for subse-group than in the Fe-CDC group (p < 0.001; Fig. 4D ). Thus, the boost of cell retention at 24 h resulted in a quent efficacy studies.
We also attempted to optimize the duration of magnet larger number of cells that eventually migrated across blood vessel walls. application. In our previous experience (9) we found that 10 min of magnet application sufficed to increase cell Magnetically Enhanced IC Delivery of CDCs retention and to improve downstream therapeutic out-Attenuates Left Ventricular Remodeling and Enhances comes. In animals receiving 5 × 10 5 Fe-CDCs we varied the Functional Benefit of Cell Therapy magnet application time for 5, 10, 20, 40 min, and 6 h. For the "6-h" animal, the magnet was mounted outside Morphometry at 3 weeks showed severe LV chamber dilatation and infarct wall thinning in the control (PBS-the chest for 5 h 20 min after the open-chest 40-min magnet application. Twenty-four hours after cell infu-infused) hearts (Fig. 5A) . In contrast, the two celltreated groups exhibited attenuated LV remodeling and sion, animals were sacrificed and the hearts were excised for fluorescent imaging. Cell retention increased better heart morphology. The protective effect was greatest in the Fe-CDC + magnet group, which had asymptotically, with a modest increase beyond 10 min (data not shown). Given that animals become more vul-more viable myocardium in the risk region ( Fig. 5B ) and thicker infarcted walls (Fig. 5D ), but smaller scar sizes nerable the longer the open-chest interval, we chose 10 min as the magnet application duration for the following (Fig. 5C ) and smaller LV cavity areas (Fig. 5E ) than the Fe-CDC group. efficacy study.
To investigate whether improved cell retention trans-Magnetically Enhanced IC Delivery Enhances lated to better functional outcomes, LVEF was assessed Short-Term Cell Retention and Long-Term Engraftment by echocardiography at baseline (24 h after I/R and treatment) and 3 weeks afterwards. Figure 6 shows rep-To assess the numbers of surviving CDCs in the injured myocardium and off-target migration into other resentative long-axis diastolic and systolic images at 3 weeks. LVEFs at baseline did not differ between treat-organs, quantitative PCR for the male-specific SRY gene was performed 24 h after cell infusion. Cell reten-ment groups, indicating a comparable degree of initial injury (Fig. 6B ). Over the next 3 weeks, LVEF declined tion/engraftment was calculated as the total number of cells detected in the heart divided by the number of progressively in the control group, but not in the Fe-CDC-treated animals. These results confirm previous infused cells (5 × 10 5 ). Magnetic targeting enhanced short-term cell retention in the recipient hearts: The Fe-findings of functional improvement after IC transplantation of CDCs (9, 11, 17, 31) or purified c-kit + cardiac cells CDC-magnet group exhibited more than fourfold greater cell retention rates than the Fe-CDC group (Fig. 4A ; (8, 13, 32) and confirm the earlier conclusion (9) that iron labeling does not undermine the therapeutic potential of p < 0.005). Moreover, fewer cells were detected in lungs from the Fe-CDC + magnet group ( Fig. 4A ; p < 0.005), CDCs. Notably, the Fe-CDC + magnet group exhibited better therapeutic outcome, with LVEF superior to the indicating decreased cell washout into the pulmonary bed, in agreement with previous works (16, 33) . No cells Fe-CDC group (p < 0.05) at 3 weeks. To facilitate comparisons, we calculated the treatment effect (i.e., the were detected in livers or spleens in either group. It was notable that the total cell retention at 24 h (heart + lung) change in LVEF at 3 weeks relative to baseline) in each group (Fig. 6C ). Controls had a negative treatment was <15% in both groups, cell death likely being the major culprit (39). To examine the effects of magnetic effect, as LVEF decreased over time. In contrast, the Fe-CDC + magnet group exhibited a sizable positive treat-targeting on long-term engraftment, subsets of animals from both groups were studied at 3 weeks. Consistent ment effect, which was even greater than that in the Fe-CDC group (p < 0.05). Taken together, we conclude that with previous findings (20, 35) , quantitative PCR revealed that both groups experienced a substantial drop a boost in cell retention/engraftment does translate into better heart morphology and greater functional benefit. (from 24 h) in surviving cells. However, the Fe-CDC + magnet group still exhibited enhanced cell engraftment
The Benefit of Magnetic Targeting Is Due to Both relative to the Fe-CDC group (Fig. 4B) . In sum, mag-Direct and Indirect Mechanisms netic targeting increases both short-term (24 h) and long-term Fe-CDC engraftment (3 weeks) in the ische-
We have found that CDCs improve cardiac function both by direct regeneration and by indirect mechanisms mia/reperfusion-injured myocardium. Because vascularly delivered cells reportedly translocate into the (10) . To further dissect the mechanism of the extra functional benefit brought about by magnetic targeting, his-parenchyma at 48-72 h (37), a subpopulation of animals was studied histologically at 72 h. Cells were found tology was performed at 3 weeks. Here, Fe-CDCs expressing GFP by lentiviral transduction was used residing in the myocardium adjacent to blood vessels in both groups (Fig. 4C) . Not surprisingly, more myocar-(rather than iron) to track stem cell fate, as SPM particles left over from cell death or exocytosis can create dium-resident cells were detected in the Fe-CDC + magnet false-positive signals for "engraftment" (35) . To assess cells (data not shown). Notably, at the 3-week time point the majority of GFP + cells were SPM − , consistent with the engraftment and phenotypic fate of transplanted Fe-CDCs, we stained sections for GFP (transplanted CDCs the concept that Fe-CDCs expel SPMs via exocytosis (2,3,38) followed by clearance by macrophages. or their progeny) and α-sarcomeric actin (cardiomyocytes). GFP + /α-sarcomeric actin + cells, taken to be cardi-Although direct regeneration was consistently detected, the absolute number of GFP + cardiomyocytes omyocytes that differentiated from delivered CDCs, were consistently detected (Fig. 7A, B) (12, 17, 31) . Con-was small and seemed insufficient to explain the functional improvement. Indeed, transplanted CDCs exert sistent with the PCR results at 3 weeks, more GFP + cells were evident in the Fe-CDC + magnet group than the their regenerative potential largely by indirect mechanisms (or paracrine effects) (10) . CDCs are rich factories Fe-CDC group, in both risk and normal regions ( Fig.  7C ; p < 0.01), defined as described previously (32) . The producing various types of proangiogenic and antiapoptotic factors such as vascular endothelial growth factor Fe-CDC + magnet group had more GFP + /α-sarcomeric actin + cells than the Fe-CDC group (Fig. 7D ; p < 0.001), (VEGF), insulin-like growth factor (IGF), stromal cellderived factor (SDF)-1, hepatocyte growth factor indicating more cardiomyocytes resulting from direct differentiation. Fluorescent images confirmed that rem-(HGF), platelet-derived growth factor (PDGF), and basic fibroblast growth factor (bFGF) (10) . Those fac-nant SPMs in the cytoplasm did not prevent Fe-CDCs from differentiating into a cardiomyocyte phenotype, as tors support endogenous repair by various mechanisms such as promoting cell cycle reentry of mature cardio-SPM + /GFP + /α-sarcomeric actin + cells were detected (data not shown). Endothelial differentiation was also myocytes, recruiting endogenous stem cells from inside and outside of the heart, and preserving myocardium confirmed by the presence of GFP + /von Willebrand + after ischemic injury. To assess indirect contributions to Iron Labeling and Magnetic Targeting Induces No Marginal Inflammation or Iron Toxicity cardiac repair, we stained heart sections 3 weeks after treatment and quantified ki67 + /α-SA + (proliferating or newly formed cardiomyocytes), c-kit + /GFP − (endoge-Mortality rates post-AMI were zero for all three groups. Three weeks after treatment, major organs were nous c-kit + cells), and TUNEL + (apoptotic) cells. Figure  8 shows that more ki67 + /α-SA + cells (green arrows) examined at necropsy; no tumor formation was found. Also, Prussian blue staining did not detect any iron clus-were detected in the Fe-CDC + magnet group (p < 0.001). Also, more endogenous c-kit + cells and fewer ters in lungs, livers, or spleens in all animal groups (Fig.  9A) . To exclude systematic iron overload caused by Fe-TUNEL + cells were found in hearts from the Fe-CDC + magnet group (data not shown). These findings reveal CDCs, serum ferritin and transferrin levels were measured at 3 weeks; these were comparable to controls in both Fe-that the benefit of extra engraftment of CDCs was due to endogenous recruitment and tissue preservation, as CDC-treated groups (Fig. 9B, C) . Also, the overall tissue density of CD68 + macrophages was similar in all three well as direct differentiation of transplanted cells. groups including controls (Fig. 9D ), further verifying that cardiac contraction, venous washout is potentiated (12) so as to undermine efficient delivery of therapeutic cells. iron labeling and/or magnetic targeting did not induce or worsen inflammation in the injured heart.
Intracoronary infusion is the most popular route of cell delivery in the clinical setting, especially after AMI, but DISCUSSION its effectiveness may be restricted by extremely low cell retention after delivery. Comparative studies have The last decade has witnessed an explosion in preclinical studies and clinical trials on stem cell therapies shown that IC delivery yields lower cell retention in the heart than intramyocardial (IM) injection. Hou et al. (16) for ischemic heart disease. Among the various types of stem cells, cardiac stem cells represent a promising can-evaluated the fate of peripheral mononuclear cells after IM and IC delivery in an ischemic/reperfusion swine didate to regenerate the injured myocardium, the place where they reside (24, 25) . Recently, CDCs (31) and model. One hour after transplantation, IM injection had greater retention (11 ± 3%) than IC delivery (2.6 ± purified c-kit + cardiac progenitor cells (CPCs) (6,7) have entered phase I-II clinical trials. Given the fact of cyclical 0.3%). Conversely, more cells were lost into pulmonary circulation IC (47 ± 1% vs. 26 ± 3% IM). In another term cell retention translated into higher engraftment, better heart morphology and greater functional benefit study, intracoronary delivery of circulating progenitor cells in post-AMI patients resulted in a 24-h cell reten-at 3 weeks. We know that CDCs and other stem cell types exhibit their therapeutic benefit by both direct tion rate of 6.9 ± 4.7% in the heart, which declined to 2 ± 1% after 3-4 days (30). In our own hands, IC infu-regeneration and other indirect mechanisms (10, 22) . The "chain reaction" of benefit enhancement by magnetic sion of CDCs 1 month post-AMI in minipigs yielded 24-h cell retention <1%. In that study, cell therapy targeting also involves both mechanisms. No incremental inflammation or iron toxicity was induced by iron reduced relative infarct size and improved hemodynamic indices, but LVEF was not improved when com-labeling and/or magnet targeting: the tissue density of CD68 + macrophages and serum concentrations of ferri-pared to placebo (17) . A subsequent study with direct IM injection in the same pig model revealed much tin and transferrin were indistinguishable in all three groups. Also, Prussian blue staining of the livers and higher 24-h cell retention (ϳ8%) and positive effects on LVEF (18).
spleens from all treatment groups did not show evident iron clusters, further confirming the safety of our strat-We sought to use magnetic enhancement/targeting to increase short-term cell retention and long-term engraft-egy. The total amount of parenteral Fe that we administered is small (0.1 mg) compared to the animal's own ment to boost therapeutic benefit, and our findings support the validity of this principle. The boost in short-iron stores (ϳ10 mg) (15). The present study has several limitations. The dosage sufficed to achieve ϳ3/4 of maximal benefit. The effects of varying magnet strength were not studied here. Also, optimization data we gained from the small animal studies may not be directly extrapolatable to large animals. With it is still unclear whether magnetic targeting exhibited all its effects by preventing cells from being washed our aortic cross-clamping procedure, cells perfuse into all three major coronary arteries while in large animal away during the transient infusion period or if it might also enhance cell adhesion to increase the chance of experiments and clinical settings, cells are only delivered into the culprit vessel. Also, the structure/anatomy transvascular relocation. Future studies will be needed (e.g., with time-lapse vital tissue imaging) to capture the difference between large-and small-animal blood vessels can add complexity to the translation. Nevertheless, details of cell migration behavior with and without magnetic targeting. Regardless, the present study further we found that IC doses of 15 × 10 6 CDCs (0.4 × 10 6 CDCs/kg) were well tolerated in minipigs, with the mid-attests to the safety and efficacy of magnetically targeted stem cell delivery in a clinically relevant animal model LAD being the only vessel infused (17) . Assuming that this territory accounts for ϳ1/3 of coronary flow (14) , and with a feasible delivery method. The approach described here is generalizable to any cell type that can we project that 1.2 × 10 6 CDCs/kg could be safely infused IC in the whole pig heart. This value is not far be delivered via the IC route. With further preclinical optimization, this approach may improve the outcome from the maximal safe dosage documented here of 5 × 10 5 CDCs per rat weighing ϳ300 g (1.7 × 10 6 CDCs/ of current cell therapy for ischemic cardiomyopathy. kg). The duration of magnetic application was not fully ACKNOWLEDGMENTS: The authors thank Drs. Rachel Smith and John Terrovitis for helpful discussions. We also optimized here, although we did establish that 10 min 
